These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Human antibody response to Zika targets type-specific quaternary structure epitopes. Collins MH; Tu HA; Gimblet-Ochieng C; Liou GA; Jadi RS; Metz SW; Thomas A; McElvany BD; Davidson E; Doranz BJ; Reyes Y; Bowman NM; Becker-Dreps S; Bucardo F; Lazear HM; Diehl SA; de Silva AM JCI Insight; 2019 Apr; 4(8):. PubMed ID: 30996133 [TBL] [Abstract][Full Text] [Related]
6. Development of Envelope Protein Antigens To Serologically Differentiate Zika Virus Infection from Dengue Virus Infection. Premkumar L; Collins M; Graham S; Liou GA; Lopez CA; Jadi R; Balmaseda A; Brackbill JA; Dietze R; Camacho E; De Silva AD; Giuberti C; Dos Reis HL; Singh T; Heimsath H; Weiskopf D; Sette A; Osorio JE; Permar SR; Miley MJ; Lazear HM; Harris E; de Silva AM J Clin Microbiol; 2018 Mar; 56(3):. PubMed ID: 29263206 [TBL] [Abstract][Full Text] [Related]
7. Identification of Anti-Premembrane Antibody as a Serocomplex-Specific Marker To Discriminate Zika, Dengue, and West Nile Virus Infections. Hsieh SC; Tsai WY; Tsai JJ; Stone M; Simmons G; Busch MP; Lanteri M; Stramer SL; Balmaseda A; Harris E; Wang WK J Virol; 2021 Sep; 95(19):e0061921. PubMed ID: 34232731 [TBL] [Abstract][Full Text] [Related]
8. Monoclonal Antibodies against Zika Virus NS1 Protein Confer Protection via Fc Yu L; Liu X; Ye X; Su W; Zhang X; Deng W; Luo J; Xiang M; Guo W; Zhang S; Xu W; Yan Q; Wang Q; Cui Y; Wu C; Guo W; Niu X; Zhang F; Lei C; Qu L; Chen L; Feng L mBio; 2021 Feb; 12(1):. PubMed ID: 33563822 [TBL] [Abstract][Full Text] [Related]
9. ZIKV-Specific NS1 Epitopes as Serological Markers of Acute Zika Virus Infection. Kam YW; Leite JA; Amrun SN; Lum FM; Yee WX; Bakar FA; Eng KE; Lye DC; Leo YS; Chong CY; Freitas ARR; Milanez GP; Proença-Modena JL; Rénia L; Costa FTM; Ng LFP; J Infect Dis; 2019 Jun; 220(2):203-212. PubMed ID: 30901054 [TBL] [Abstract][Full Text] [Related]
10. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization. Lin HH; Yang SP; Tsai MJ; Lin GC; Wu HC; Wu SC Theranostics; 2019; 9(16):4811-4826. PubMed ID: 31367259 [TBL] [Abstract][Full Text] [Related]
11. Cross-Reactivity and Anti-viral Function of Dengue Capsid and NS3-Specific Memory T Cells Toward Zika Virus. Lim MQ; Kumaran EAP; Tan HC; Lye DC; Leo YS; Ooi EE; MacAry PA; Bertoletti A; Rivino L Front Immunol; 2018; 9():2225. PubMed ID: 30327651 [TBL] [Abstract][Full Text] [Related]
12. A single-dose circular RNA vaccine prevents Zika virus infection without enhancing dengue severity in mice. Liu X; Li Z; Li X; Wu W; Jiang H; Zheng Y; Zhou J; Ye X; Lu J; Wang W; Yu L; Li Y; Qu L; Wang J; Li F; Chen L; Wu L; Feng L Nat Commun; 2024 Oct; 15(1):8932. PubMed ID: 39414822 [TBL] [Abstract][Full Text] [Related]
13. Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection. Khandia R; Munjal A; Dhama K; Karthik K; Tiwari R; Malik YS; Singh RK; Chaicumpa W Front Immunol; 2018; 9():597. PubMed ID: 29740424 [TBL] [Abstract][Full Text] [Related]